Association of rash with improved outcomes by the addition of cetuximab (C) to second-line mitoxantrone plus prednisone (MP) for progressive mCRPC after docetaxel-based chemotherapy.Nicholas Vogelzang, MD, Comprehensive Cancer Centers of NevadaPaul Conkling, MD, Virginia Oncology AssociatesManuel Modiano, MD, Arizona Oncology Associates
An open-label, multicenter, randomized Phase Ib/II study of eribulin mesylate administered in combination with gemcitabine plus cisplatin versus gemcitabine plus cisplatin alone as first line therapy for locally advanced or metastatic bladder cancer.Marcus Neubauer, MD, Jody S. Garey, PharmD, Greg Nelson, Debra Patt, MD, Tom Cartwright, MD, Russ Hoverman, MD, Leslie T. Busby, MD, Barry Brooks, MD, Mark Sitarik, MD, Mike Kolodziej, MD, Roger Anderson Dr PH, Roy Beveridge, MD; on behalf of the US Oncology Pathways Task Force and Clinical Content Development Team
Bevacizumab therapy in advanced non-small cell lung cancer (NSCLC): outcomes from a community oncology network.Mark Fleming, MD, Virginia Oncology AssociatesJohn Burke, MD, Rocky Mountain Cancer CentersJohn R. Caton, MD, Willamette Valley Cancer Institute and Research CenterGuru Sonpavde, MD, Texas Oncology
Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP).Aimee L. Ginsburg, PharmD, Debra M. Patt MD, Jennifer Flinn, Janet L. Espirito, PharmD, Marcus A. Neubauer, MD, J. Russell Hoverman, MD, PhD, Thomas H. Cartwright, MD, Leslie T. Busby, MD, Barry Don Brooks, MD, Michael A. Kolodziej, MD, Mark A. Sitarik, MD; on behalf of the US Oncology Pathways Task Force and Clinical Content Development T
|SOURCE US Oncology, Inc.|
Copyright©2010 PR Newswire.
All rights reserved